BBOT to Participate in the Jefferies Global Healthcare Conference in London
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced that its leadership team will present at the Jefferies Global Healthcare Conference on Monday, November 17, 2025 at 2:30 p.m. GMT. A live webcast will be available on the company’s Events page at https://investors.bbotx.com/news-events/events. A replay of the webcast will be accessible for at least 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – BBOT
In the Nov 4 session, BBOT declined 1.55%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.
A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. A replay of the webcast will be available for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
